Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11 2021 - 9:05AM
Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the
“Company”), a clinical-stage biopharmaceutical company primarily
focused on the development of novel drugs that are designed to
deter abuse in the treatment of CNS disorders, today announced the
appointment of Leanne Kelly as its Chief Financial Officer.
Ms. Kelly is an accomplished financial executive
with over 20 years of experience leading private and publicly
traded companies across life science, technology and e-Commerce
sectors and a foundation in public accounting.
“Following our IPO earlier this year, we have
taken thoughtful steps to strengthen our team and ensure we have
key people with the right expertise needed to best position the
Company for success. Leanne is a great addition to the Vallon
executive management team as CFO and her industry experience
and professional track record are perfectly aligned with the
Company’s strategic priorities in the near and long term,”
commented David Baker, President & Chief Executive Officer of
Vallon.
Prior to joining Vallon, she most recently
served as the Controller and Executive Director, Global Financial
Reporting at OptiNose, Inc. a $50M revenue specialty pharmaceutical
company. Over the course of her career, she has held Senior Vice
President of Finance, Controller and Chief Financial Officer
positions in private and public companies such as Flower
Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation.
Ms. Kelly began her career as an auditor with KPMG LLP. While
serving in those roles, Ms. Kelly's work included multi-million
dollar financings, M&A diligence and support. She also has
experience in financial oversight, internal and external financial
reporting, forecasting, and financial analysis, as well as investor
and public relations.
“Vallon truly represents an exciting opportunity
for me with the recently completed IPO and its lead clinical
development program, ADAIR, on target for pivotal data readout in
the second half of this year,” added Ms. Kelly. “I look forward to
leveraging the knowledge and tools amassed over my career to help
propel us to our next phase of growth.”
Ms. Kelly received her Bachelor of Science
degree in Business Economics with a concentration in Accounting
from Lehigh University, and is a licensed CPA (inactive status) in
the state of Pennsylvania.
About Vallon Pharmaceuticals
Inc.
Vallon Pharmaceuticals Inc. is a clinical-stage
biopharmaceutical company, headquartered in Philadelphia, PA. The
Company is focused on the development of new medications to help
patients with central nervous system (CNS) disorders. The Company’s
lead investigational product candidate, ADAIR, is a novel abuse
deterrent formulation of amphetamine immediate release being
developed for the treatment of ADHD and narcolepsy.
For more information about the company, please
visit www.vallon-pharma.com.
Forward Looking Statements
This press release contains “forward-looking
statements” that are based on Vallon’s current expectations and
subject to inherent uncertainties, risks and assumptions that are
difficult to predict, including, without limitation, Vallon’s
ability to execute its business plan, continue its growth and fund
its ongoing business activities as planned, Vallon’s ability to
develop and commercialize its product candidates, expectations
related to results of clinical trials and studies, Vallon’s
expectations with respect to the important advantages it believes
its abuse-deterrent formulation of drugs have over similar drugs in
the market, and the growing need for abuse-deterrent formulations
of drugs, Vallon’s ability to utilize the 505(b)(2) regulatory
pathway, and Vallon’s ability to obtain FDA approval of ADAIR and
its other product candidates. Forward-looking statements may be
identified by the use of words such as “anticipate,” “believe,”
“contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,”
“may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will,” “would,” or the negative of
these words or other similar expressions. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Item
1A. Risk Factors” in our Annual Report on Form 10-K, filed with the
U.S. Securities and Exchange Commission on March 29, 2021.
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Investor Contact:JTC Team,
LLCJenene Thomas(833) 475-8247vallon@jtcir.com
Vallon Pharmaceuticals (NASDAQ:VLON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vallon Pharmaceuticals (NASDAQ:VLON)
Historical Stock Chart
From Apr 2023 to Apr 2024